Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
ALPS
Valuation N/A
Alps Group Inc
Price$0.37
Model IV—
P/IV—
Limited data — see page
ATPC
Deeply overvalued
Agape ATP Corp
Price$2.11
Model IV$1.03
P/IV1.97
Premium +105%
Return to IV: -51.3%
Market implies +7.7%/yr
vs model +10.7% · in line
DCGO
Deeply undervalued
DocGo Inc.
Price$0.34
Model IV$1.22
P/IV0.29
Discount 72%
Return to IV: +260.9%
Market implies -20.3%/yr
vs model +7.1% · below model
EUDA
Deeply overvalued
EUDA Health Holdings Ltd
Price$18.60
Model IV$9.57
P/IV1.89
Premium +94%
Return to IV: -48.5%
Market implies -4.3%/yr
vs model +10.6% · below model
EUDAW
Valuation N/A
EUDA Health Holdings Ltd
Price$0.02
Model IV—
P/IV—
Market implies -50.0%/yr
INNV
Deeply overvalued
InnovAge Holding Corp.
Price$9.11
Model IV$2.09
P/IV3.63
Premium +335%
Return to IV: -77.0%
Market implies +26.4%/yr
vs model +8.3% · above model
LDDD
Valuation N/A
Longduoduo Co Ltd
Price$0.51
Model IV—
P/IV—
Market implies +23.4%/yr
LFST
Deeply overvalued
LifeStance Health Group, Inc.
Price$12.06
Model IV$3.24
P/IV2.38
Premium +272%
Return to IV: -73.1%
Market implies +31.4%/yr
vs model +17.6% · above model
OMDA
Deeply undervalued
Omada Health, Inc.
Price$20.82
Model IV$54.67
P/IV0.33
Discount 62%
Return to IV: +162.6%
Market implies -17.2%/yr
vs model +45.6% · below model
PIII
Valuation N/A
P3 Health Partners Inc.
Price$5.31
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +26.0% · below model
PIIIW
Valuation N/A
P3 Health Partners Inc.
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +26.0% · below model
PNTG
Deeply overvalued
Pennant Group, Inc.
Price$40.37
Model IV$18.04
P/IV2.20
Premium +124%
Return to IV: -55.3%
Market implies +18.9%/yr
vs model +11.5% · above model
PRVA
Fairly valued
Privia Health Group, Inc.
Price$20.19
Model IV$17.71
P/IV1.21
Premium +14%
Return to IV: -12.3%
Market implies +15.6%/yr
vs model +18.2% · in line
SRTA
Valuation N/A
Strata Critical Medical, Inc.
Price$4.47
Model IV—
P/IV—
Market implies +5.8%/yr
vs model +40.6% · below model
TALK
Fairly valued
Talkspace, Inc.
Price$5.25
Model IV$4.75
P/IV1.09
Premium +10%
Return to IV: -9.5%
Market implies -4.2%/yr
vs model +19.1% · below model
TALKW
Valuation N/A
TALKW
Price$0.00
Model IV—
P/IV—
Limited data — see page
USPH
Fairly valued
U S PHYSICAL THERAPY INC /NV
Price$83.52
Model IV$77.07
P/IV1.07
Premium +8%
Return to IV: -7.7%
Market implies +8.5%/yr
vs model +10.6% · in line
VSEE
Valuation N/A
VSEE HEALTH, INC.
Price$2.10
Model IV—
P/IV—
Market implies +4.2%/yr
vs model +15.0% · below model
WGS
Deeply overvalued
GeneDx Holdings Corp.
Price$67.73
Model IV$30.32
P/IV2.81
Premium +123%
Return to IV: -55.2%
Market implies +12.4%/yr
vs model +19.1% · below model